Published in Vaccine Weekly, August 11th, 1997
The vaccine was developed by Genzyme Transgenics Corp., Framingham, Massachusetts. The clinical trial was conducted by researchers at the U.S. National Cancer Institute (NCI) and University of Arkansas for Medical Sciences (UAMS).
The tumor-specific response experienced by patients in the trial indicates the vaccine's potential ability to reduce or eliminate residual cancer in patients who have not responded to other therapies. Based on these preliminary results, the company will accelerate vaccine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.